Related Experiment Video
Updated: Jun 8, 2026
05:38
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Parkinson's disease and motor fluctuations
1Medical University of South Carolina, 326 Calhoun Street, Suite 308, Charleston, SC, 29425, USA, hinsonvk@musc.edu.
Current Treatment Options in Neurology
|September 16, 2010
Summary
Managing Parkinson's disease (PD) involves preventing motor fluctuations with early, low-dose dopaminergic therapy. Advanced treatments like deep brain stimulation (DBS) are considered when medications fail.
Area of Science:
- Neurology
- Movement Disorders
- Pharmacology
Background:
- Significant advancements in Parkinson's disease (PD) treatment have improved patient quality of life.
- Long-term dopaminergic therapy can lead to disabling motor fluctuations, including wearing-off phenomena and dyskinesias.
Purpose of the Study:
- To outline strategies for preventing and managing motor fluctuations and dyskinesias in Parkinson's disease.
- To guide clinicians in optimizing treatment to maintain functional status and minimize complications.
Main Methods:
- Emphasizes a proactive approach, starting with low-dose dopaminergic therapy targeting specific symptoms in early PD.
- Discusses the use of alternative medications like dopamine agonists, amantadine, and rasagiline to delay motor fluctuations.
- Details sequential treatment escalation for motor fluctuations and dyskinesias, including levodopa adjustments and adjunctive therapies.
- Considers deep brain stimulation (DBS) as a surgical option for refractory cases.
Main Results:
- Early intervention with low-dose, targeted dopaminergic therapy can prevent or delay motor complications.
- A stepwise approach to managing 'off' time and dyskinesias is effective, involving medication adjustments and additions.
- Deep brain stimulation (DBS) offers a viable alternative when medical management is insufficient.
Conclusions:
- Preventive strategies focusing on early, individualized dopaminergic therapy are crucial for managing Parkinson's disease.
- A tiered approach to pharmacotherapy and consideration of DBS are essential for addressing motor fluctuations and dyskinesias.
- Optimizing treatment for Parkinson's disease requires careful patient selection and skilled intervention, including surgical options.
Related Concept Videos
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:12Alterations in Muscle Tone ll
Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...